About this trial
This study will observe and compare patient experience during outpatient diagnostic endoscopic ultrasound (EUS) when moderate sedation is provided with either remimazolam plus fentanyl or midazolam plus fentanyl, according to routine clinical practice.
Both sedation approaches are currently used in standard care. The choice of sedative will be made by the treating physician as part of usual practice and not assigned by the study. The purpose of the study is to evaluate how patients tolerate the procedure with each sedation strategy, focusing on comfort, recovery, and overall procedural experience.
After the procedure, participants will be asked to complete questionnaires about their experience at 1 hour and 24 hours after EUS. The study will also collect information on sedation effectiveness, operator satisfaction, recovery time, adverse events, and costs.
This is a prospective observational single-center study involving adult outpatients undergoing diagnostic EUS. Information collected during routine care, including vital signs, recovery measures, and procedural data, will be analyzed to compare outcomes between the two sedation approaches.
Eligibility criteria
Qualifiers
Age > 18 years
Outpatients undergoing diagnostic EUS (upper GI or biliopancreatic)
Informed consent obtained
Disqualifiers
Known allergy to study medications
Recent upper respiratory infection or asthma attack
History of sedative or opioid addiction
Advanced oncologic disease with peritoneal metastases
Trial design
Treatments tested in this trial
- Not listed